Completed PHASE2 INTERVENTIONAL 1-arm NCT03848143

Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain

Intraoral Administration of Onabotulinum Toxin A for Continuous Neuropathic Pain: a Single Subject Experimental Design

Sponsor: AbbVie

Updated 10 times since 2019 Last updated: Jul 29, 2025 Started: Sep 11, 2019 Primary completion: Jun 30, 2025 Completion: Jun 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Neuropathic Pain, this trial is completed. The trial is conducted by AbbVie and has accumulated 10 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 5 earlier versions

Jan 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Jan 2022 — Jan 2023 [monthly]

Recruiting PHASE2
Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Oct 2019 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2019 — Oct 2019 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie
Isabel Moreno Hay

Data source: University of Kentucky

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lexington, United States